All In Biotech

Drug Trial Radar · NCT05216835

Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma.

Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

45

Actual

Start

Mar 18, 2022

Primary completion

Aug 30, 2024

Study completion Sep 4, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Feb 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 101 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sabestomig (AZD7789) in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL).

Conditions

  • Relapsed or Refractory Classical Hodgkin Lymphoma

Interventions

  • Sabestomig (AZD7789)Drug

    Patients will receive sabestomig (PD-1/TIM-3 bispecific monoclonal antibody) via intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A (Dose Escalation): Number of Participants With Adverse Events (AEs)Time frame: From start of treatment [Cycle 1 Day 1 (C1D1) (each cycle was 28 days)] up to 90 days post last dose (approximately 2 years 5 months)
  2. Part A (Dose Escalation): Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: From first dose (C1D1) until 28 days for each participant [within 28 days DLT period]
  3. Part B (Dose Expansion): Cohort B1: Objective Response Rate (ORR)Time frame: Up to approximately 2 years 90 days
  4. Part B (Dose Expansion): Cohort B2: Complete Response Rate (CRR)Time frame: Up to approximately 2 years 90 days
  5. Part B (Dose Expansion): Number of Participants With AEsTime frame: Up to approximately 2 years 90 days

Locations

14 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    Duarte, California

  • Research Site

    Miami, Florida

  • Research Site

    Rochester, Minnesota

  • Research Site

    New York, New York

  • Research Site

    Houston, Texas

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    København Ø, Denmark

  • Research Site

    Lille, France

  • Research Site

    Bologna, Italy

  • Research Site

    Naples, Italy

  • Research Site

    Valencia, Spain

  • Research Site

    Manchester, United Kingdom

  • Research Site

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.